Valora Therapeutics’ antibody lectin chimeras, or AbLecs, target glyco-immune checkpoints, pathways that modulate cellular communication with the immune system. The startup’s science is based on research from Carolyn Bertozzi, a Stanford professor who was awarded the 2022 Nobel Prize in Chemistry.
The post Startup Valora Unveils a Sweet Way to Stop Cancer and Autoimmune Disease, Plus $30M for R&D appeared first on MedCity News.
